Molecule News and Research

RSS

Scientists discover two body clock genes that may help find treatments for seasonal affective disorder

Scientists have discovered two "body clock" genes that reveal how seasonal changes in hormones are controlled and could ultimately help find treatments for seasonal affective disorder.

3 May 2010

Mutations in several genes associated with developmental brain disorder: Study

Although there is no known cause of autism, studies have shown that mutations in several genes are associated with the developmental brain disorder. New research has uncovered two additional genes that may be involved with autism.

3 May 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

Researchers identify key protein that regulates innate immune system

A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

Nanotechnology for study of individual molecule interaction in live cells

A University of Alberta-led research team has taken a major step forward in understanding how T cells are activated in the course of an immune response by combining nanotechnology and cell biology. T cells are the all important trigger that starts the human body's response to infection.

29 Apr 2010

Ago2 protein helps generate microRNAs: CSHL researchers

MicroRNAs are small bits of RNA within cells that wield enormous power. They influence virtually every biological process by controlling the "expression" of genes. Helping them in exerting this control is a unique class of proteins called Argonautes.

29 Apr 2010

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Lycera Corporation, a biopharmaceutical company pioneering an innovative approach to developing novel oral medicines to treat autoimmune diseases, today announced that the company has made important progress, triggering a second tranche of $11 million in its Series A financing. Proceeds from the second tranche will be used to continue to advance Lycera's discovery and development efforts and further support the growth of the company.

29 Apr 2010

Celera reports net loss of $12.5M for first-quarter 2010

Celera Corporation today reported net revenues of $31.4 million for the first quarter of 2010 that ended March 27, 2010, compared to $45.7 million in the prior year quarter. For the first quarter of 2010, Celera reported a net loss $12.5 million, or $0.15 per share, compared to a net loss of $1.4 million, or $0.02 per share, for the prior year quarter.

28 Apr 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

When the human body becomes infected with new influenza viruses, the immune system rapidly activates an inborn protective mechanism to inhibit the intruding pathogen. A protein known as Mx plays an important role in this process, keeping the spread of viruses in check. Exactly how Mx accomplishes this task was previously unknown.

28 Apr 2010

IMB awards manufacturer licenses to PPD’s Athlone facility

PPD, Inc. today announced its contract research facility in Athlone, Ireland, has been awarded manufacturer licenses by the Irish Medicines Board. The licenses support investigational medicinal products and marketed products and provide laboratory certifications for quality control of medicinal products.

28 Apr 2010

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the first patient in a Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305.

27 Apr 2010

PositiveID, Receptors announce milestone in development of in vivo glucose-sensing RFID microchip

PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that the companies have achieved a milestone in the development of their in vivo glucose-sensing RFID microchip to detect glucose levels in the body. The companies have completed the synthesis of a new chemical building block that will serve as the anchor of their next generation of Combinatorial Artificial Receptor (CARA™) surfaces for the sensing system component of the implantable glucose sensor.

27 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

New method helps study interactions needed for formation of lipopolysaccharides

Scientists have combined chemistry and biology research techniques to explain how certain bacteria grow structures on their surfaces that allow them to simultaneously cause illness and protect themselves from the body's defenses.

26 Apr 2010

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

Temperature-sensing ability in proteins remain a mystery

Scientists at The Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation (GNF) have shed new light on the molecular mechanism that enables us to sense temperature, such as the heat from a sizzling stove. In addition to contributing to our knowledge of basic biology, the findings could one day lead to new therapies for conditions such as acute or chronic inflammatory pain.

24 Apr 2010

Molecule News and Research

Scientists discover two body clock genes that may help find treatments for seasonal affective disorder

Mutations in several genes associated with developmental brain disorder: Study

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Researchers identify key protein that regulates innate immune system

Canadian researchers identify new therapeutic target for lung cancer

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Nanotechnology for study of individual molecule interaction in live cells

Ago2 protein helps generate microRNAs: CSHL researchers

Lycera to advance discovery, development efforts with second tranche of $11 million Series A financing

Celera reports net loss of $12.5M for first-quarter 2010

Stalk structure of Mx protein restrains components of influenza virus in infected cells

IMB awards manufacturer licenses to PPD’s Athlone facility

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

PositiveID, Receptors announce milestone in development of in vivo glucose-sensing RFID microchip

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Researchers synthesize metal compounds that can be effective in treatment of cancer

New method helps study interactions needed for formation of lipopolysaccharides

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Temperature-sensing ability in proteins remain a mystery

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News